Fig. 2

Plasma concentrations of cTnT and cTnI in patients based on substance use disorder and cardiovascular disease diagnosis. (a) Bars represent estimated marginal means and 95% CI of back-transformed values from log (10)-transformed cTnT concentrations (pg/mL), based on primary substance use disorder and cardiovascular disease diagnosis; (b) Bars are estimated marginal means and 95% CI of back-transformed values from log (10)-transformed cTnI concentrations (pg/mL), based on primary substance use disorder and cardiovascular disease diagnosis; (c) Bars are estimated marginal means and 95% CI of back-transformed values from log (10)-transformed cTnT concentrations (pg/ml), based on substance use disorder diagnosis in the non-CV group; (d) Bars are estimated marginal means and 95% CI of back-transformed values from log (10)-transformed cTnI concentrations (pg/mL), based on substance use disorder diagnosis in the non-CV group. (*) indicates p < 0.05 compared to the alcohol and non-CV subgroup. The dashed arrows represent concentrations for the control group. (a) and (b) were analyzed using a two-way ANCOVA with primary substance use disorder (f₁) and cardiovascular disease (f₂) as factors, controlling for age, BMI, and sex; (c) and (d) were analyzed using a one-way ANCOVA with substance use disorder diagnosis as the factor, controlling for age, BMI, and sex.